Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability

References

• Sartorius N. The economic and social burden of depression. J Clin Psychiatry. 2001;62 Suppl 15(15):8–11.
   PubMedGoogle Scholar
• Malhi GS, Mann JJ. Depression. Lancet. 2018 Nov 24;392(10161):2299–2312.
   PubMed Web of Science ®Google Scholar
• Penn E, Tracy DK. The drugs don’t work? antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol. 2012 Oct;2(5):179–188.
   PubMedGoogle Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Feltes KP, Doorduin J, Klein HC, et al. Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol. 2017 Sep;31(9):1149–1165.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Bouso JC, Alcázar-Córcoles M, et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018 Sep;11(9):889–902.
   PubMed Web of Science ®Google Scholar
• Psiuk D, Nowak E, Cholewa K, et al. The Potential Role of Serotonergic Hallucinogens in Depression Treatment. Life (Basel, Switzerland). 2021 Jul 29;11(8). DOI:10.3390/life11080765
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Osório FL, Crippa JA, et al. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry. 2016 Mar;38(1):65–72.
   PubMed Web of Science ®Google Scholar
• Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003 Jul;306(1):73–83.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998 Dec 1;9(17):3897–3902.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Enzler F, Gasser P, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015 Oct 15;78(8):544–553.
   PubMed Web of Science ®Google Scholar
• Preller KH, Pokorny T, Hock A, et al. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci U S A. 2016 May 3;113(18):5119–5124.
   PubMed Web of Science ®Google Scholar
• Fortunato JJ, Réus GZ, Kirsch TR, et al. Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1425–1430.
   PubMed Web of Science ®Google Scholar
• Fortunato JJ, Réus GZ, Kirsch TR, et al. Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. J Neural Transm (Vienna). 2010 Oct;117(10):1131–1137.
   PubMed Web of Science ®Google Scholar
• Fortunato JJ, Réus GZ, Kirsch TR, et al. Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res Bull. 2010 Mar 16;81(4–5):491–496.
   PubMed Web of Science ®Google Scholar
• Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996 Feb;184(2):86–94.
   PubMed Web of Science ®Google Scholar
• Barbosa PC, Giglio JS, Dalgalarrondo P. Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs. 2005 Jun;37(2):193–201.
   PubMed Web of Science ®Google Scholar
• Da Silveira DX, Grob CS, de Rios Md, et al. Ayahuasca in adolescence: a preliminary psychiatric assessment. J Psychoactive Drugs. 2005 Jun;37(2):129–133.
   PubMed Web of Science ®Google Scholar
• Bouso JC, González D, Fondevila S, et al. Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study. PLoS One. 2012;7(8):e42421.
   PubMed Web of Science ®Google Scholar
• Uthaug MV, van Oorsouw K, Kuypers KPC, et al. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology (Berl). 2018 Oct;235(10):2979–2989.
   PubMed Web of Science ®Google Scholar
• Ona G, Kohek M, Massaguer T, et al. Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs. 2019 Apr-Jun;51(2):135–145.
   PubMed Web of Science ®Google Scholar
• Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of ayahuasca on mental health and quality of life in naïve users: a longitudinal and cross-sectional study combination. Sci Rep. 2020 Mar 5;10(1):4075.
   PubMed Web of Science ®Google Scholar
• Giovannetti C, Garcia Arce S, Rush B, et al. Pilot evaluation of a residential drug addiction treatment combining traditional Amazonian medicine, ayahuasca and psychotherapy on depression and anxiety. J Psychoactive Drugs. 2020 Nov-Dec;52(5):472–481.
   PubMed Web of Science ®Google Scholar
• Osório Fde L, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015 Jan-Mar;37(1):13–20.
   PubMedGoogle Scholar
• Sanches RF, de Lima Osório F, Dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016 Feb;36(1):77–81.
   PubMed Web of Science ®Google Scholar
• Zeifman RJ, Wagner AC, Watts R, et al. Post-psychedelic reductions in experimental avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry. 2020;11:782–783.
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019 Mar;494:655–663.** First randomized, double-blind, placebo-controlled trial of ayahuasca in treatment-resistant major depressive disorder
   PubMed Web of Science ®Google Scholar
• de Almeida Rn, Galvão ACDM, da Silva Fs, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol. 2019;10:1234.
   PubMed Web of Science ®Google Scholar
• Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J Psychopharmacol. 2020;34(10):1125–1133.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Balthazar FM, Bouso JC, et al. The current state of research on ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol. 2016 Dec;30(12):1230–1247.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Hallak JE. Effects of the natural β-carboline alkaloid harmine, a main constituent of ayahuasca, in memory and in the hippocampus: a systematic literature review of preclinical studies. J Psychoactive Drugs. 2017 Jan-Mar;49(1):1–10.
   PubMed Web of Science ®Google Scholar
• Katchborian-Neto A, Santos WT, Nicácio KJ, et al. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: applicability to Parkinson’s disease. J Ethnopharmacol. 2020 Jun 12;255:112743.
   PubMed Web of Science ®Google Scholar
• Morales-García JA, de la Fuente Revenga M, Alonso-Gil S, et al. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep. 2017 Jul 13;7(1):5309.
   PubMedGoogle Scholar
• Inserra A; Inserra A. Hypothesis: the psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process. Front Pharmacol. 2018;9:330.
   PubMed Web of Science ®Google Scholar
• Callaway JC, McKenna DJ, Grob CS, et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol. 1999 Jun;65(3):243–256.
   PubMed Web of Science ®Google Scholar
• Riba J, Rodriguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001 Feb;154(1):85–95.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Valle M, Bouso JC, et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011 Dec;31(6):717–726.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Grasa E, Valle M, et al. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology (Berl). 2012 Feb;2194:1039–53. * First and Only study to evaluate the effects of two consecutive doses of ayahuasca.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Osorio FL, Rocha JM, et al. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):540–550.
   PubMed Web of Science ®Google Scholar
• Rocha JM, Rossi GN, de Lima Osorio F, et al. Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers: a pilot, proof-of-concept, randomized controlled trial. J Clin Psychopharmacol. 2021 May-Jun 01;41(3):267–274.
   PubMed Web of Science ®Google Scholar
• Durante I, Dos Santos RG, Bouso JC, et al. Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. Braz J Psychiatry. 2021 Jul-Aug;43(4):362–369.
   PubMedGoogle Scholar
• Muller F, Borgwardt S. Acute Effects of Lysergic Acid Diethylamide (LSD) on Resting Brain Function. Swiss Med Wkly. 2019 Sep 23;149:w20124.
   PubMed Web of Science ®Google Scholar
• Bienemann B, Ruschel NS, Campos ML, et al. Self-reported negative outcomes of psilocybin users: a quantitative textual analysis. PLoS One. 2020;15(2):e0229067.
   PubMed Web of Science ®Google Scholar
• Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry - Current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry. 2021 Jul;54(4):176–190.
   PubMedGoogle Scholar
• Goldberg SB, Shechet B, Nicholas CR, et al. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Psychol Med. 2020 Dec;50(16):2655–2666.
   PubMed Web of Science ®Google Scholar
• Wieckiewicz G, Stoklosa I, Piegza M, et al. Lysergic acid diethylamide, psilocybin and dimethyltryptamine in depression treatment: a systematic review. Pharmaceuticals (Basel). 2021 Aug 12;14(8):793.
   PubMedGoogle Scholar
• Pasquini L, Palhano-Fontes F, Araujo DB. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J Psychopharmacol. 2020 Jun;34(6):623–635.
   PubMed Web of Science ®Google Scholar
• Riba J, Rodriguez-Fornells A, Barbanoj MJ. Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl). 2002 Dec;165(1):18–28.
   PubMed Web of Science ®Google Scholar
• Riba J, Romero S, Grasa E, et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006 May;186(1):93–98.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Landeira-Fernandez J, Strassman RJ, et al. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007 Jul 25;112(3):507–513.
   PubMed Web of Science ®Google Scholar
• Tort S, Urrútia G, Nishishinya MB, et al. Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2012; Apr 18(4):Cd009807. DOI:10.1002/14651858.CD009807
   PubMed Web of Science ®Google Scholar
• Brubacher JR, Ravikumar PR, Bania T, et al. Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest. 1996 Nov;110(5):1282–1288.
   PubMed Web of Science ®Google Scholar
• Ermakova AO, Dunbar F, Rucker J, et al. A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol. 2021;36(3):273–294.
   Web of Science ®Google Scholar
• Stoyek MR, Jonz MG, Smith FM, et al. Distribution and chronotropic effects of serotonin in the zebrafish heart. Auton Neurosci. 2017 Sep;206:43–50.
   PubMed Web of Science ®Google Scholar
• Watts SW, Morrison SF, Davis RP, et al. Serotonin and blood pressure regulation. Pharmacol Rev. 2012 Apr;64(2):359–388.
   PubMed Web of Science ®Google Scholar
• Paredes S, Cantillo S, Candido KD, et al. An association of serotonin with pain disorders and Its modulation by estrogens. Int J Mol Sci. 2019 Nov 15;20(22):5729.
   Web of Science ®Google Scholar
• Rizzoli P, Mullally WJ. Headache. Am J Med. 2018 Jan;131(1):17–24.
   PubMed Web of Science ®Google Scholar
• Labate B, de Rose I, Dos Santos R. Ayahuasca religions: a comprehensive bibliography and critical essays. Santa Cruz: Multidisciplinary Association for Psychedelic Studies; 2009.
   Google Scholar
• Serrano-Dueñas M, Cardozo-Pelaez F, Sanchez-Ramos J. Effects of Banisteriopsis caapi extract on Parkinson’s disease. Sci Rev Alternative Med. 2001 06 /01;.;5:127–132.
   Google Scholar
• Djamshidian A, Bernschneider-Reif S, Poewe W, et al. Banisteriopsis caapi, a forgotten potential therapy for Parkinson’s disease? Mov Disord Clin Pract. 2015;3(1):19–26.
   PubMedGoogle Scholar
• Banerjee R, Kumar M, Gaurav I, et al. In-silico prediction of the beta-carboline alkaloids harmine and harmaline as potent drug candidates for the treatment of Parkinson’s disease. Antiinflamm Antiallergy Agents Med Chem. 2021;20(3):250–263.
   PubMedGoogle Scholar
• Pennes HH, Hoch PH. Psychotomimetics, clinical and theoretical considerations: harmine, win-2299 and nalline. Am J Psychiatry. 1957 Apr;113(10):887–892.
   PubMed Web of Science ®Google Scholar
• Khan H, Patel S, Kamal MA. Pharmacological and toxicological profile of harmane-β-carboline alkaloid: friend or foe. Curr Drug Metab. 2017;18(9):853–857.
   PubMed Web of Science ®Google Scholar
• Brito-da-Costa AM, Dias-da-silva D, Gomes NGM, et al. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: clinical and forensic impact. Pharmaceuticals. (Basel, Switzerland). 2020;13(11): 334.
   Web of Science ®Google Scholar
• Houle SKD, Evans D, Carter CA, et al. Ayahuasca and the traveller: a scoping review of risks and possible benefits. Travel Med Infect Dis. 2021 Nov-Dec;44:102206.
   PubMed Web of Science ®Google Scholar
• Zhao T, He YQ, Wang J, et al. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother Res. 2011 Nov;25(11):1671–1677.
   PubMed Web of Science ®Google Scholar
• Li S-P, Wang Y-W, Qi S-L, et al. Analogous β-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front Pharmacol. 2018;9:346.
   PubMed Web of Science ®Google Scholar
• Jiang B, Meng L, Zou N, et al. Mechanism-based pharmacokinetics-pharmacodynamics studies of harmine and harmaline on neurotransmitters regulatory effects in healthy rats: challenge on monoamine oxidase and acetylcholinesterase inhibition. Phytomedicine. 2019 Sep;62:152967.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Chiappini S, Papanti D, et al. How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy. Hum Psychopharmacol. 2020 May;35(3):e2728.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Chiappini S, Papanti D, et al. The bridge between classical and “synthetic”/chemical psychoses: towards a clinical, psychopathological, and therapeutic perspective. Front Psychiatry. 2019;10:851.
   PubMed Web of Science ®Google Scholar
• Szmulewicz AG, Valerio MP, Smith JM. Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report. Int J Bipolar Disord. 2015;3(1):4.
   PubMedGoogle Scholar
• Zellner N, Zellner T, Warninghoff J. Ayahuasca-induced psychosis in a patient with bipolar disorder. Nervenarzt. 2019 Nov;90(11):1154–1155.
   PubMed Web of Science ®Google Scholar